Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

PD
A 3-Year, Prospective, Randomized, Controlled Study on Amino Acid Dialysate in Patients on CAPD - Li FK, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
A Budget Impact Model (BIM) for Expanded Haemodialysis (HDx) vs. High-Flux Haemodialysis (HF-HD) in Two Major Public Health Sectors, Kingdom of Saudi Arabia (KSA)
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
A comparison between the most used new medium cut-off membranes in removal of medium molecules
Visit resource site
PD
A controlled trial of two biocarbonate-containing dialysis fluids for CAPD - final report - Coles GA, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
A Global Study Assessing Albumin Levels on Expanded Hemodialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear)
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
A Randomised Study Investigating the Effect of Medium Cut-Off Haemodialysis on Markers of Vascular Health Compared with Online Haemodiafiltration (MoDal Study)
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
A randomized prospective cross over study on the effects of medium cut-off membranes on T cellular and serologic immune phenotypes in hemodialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
A Randomized, Open-Label, Crossover Clinical Study to Compare the Effect of Hemodialysis Performed With a Medium Cut-Off Membrane vs. That With a High-Flux Membrane on Endothelial Function
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
A Trial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in Hemodialysis Patients: A Safety Device Study
Visit resource site
HD
Acetate-free, citrate-acidified bicarbonate dialysis improves serum calcification propensity-a preliminary study. Lorenz G, et al.
Visit resource site
HD
Acute effect of citrate bath on postdialysis alkalaemia - De Sequera Ortiz P, et al.
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.